Phase 1:
The first step was to quickly identify the most attractive and available compounds, or drugs in development, that would be good candidates for developing the portfolio. Working closely with the client, the McKinsey team scanned a vast library of pipeline compounds, fully assessing the profitability of various therapeutic areas and disease states, trends in populations, unmet medical need, and strategic fit. The team also tapped not only the client's knowledge and experience but also that of McKinsey and external experts worldwide. As a result of this intensive analysis, the team quickly narrowed 1,200 potential leads to 18 priority compounds, and finally, to 6 viable licensing candidates.